Diclofenac Epolamine
Generic Name: diclofenac epolamine
Brand Names:
Licart
LICART is a 10 cm x 14 cm topical system containing 1.3% diclofenac epolamine (182 mg per patch). The active ingredient is an NSAID presented as a topical adhesive system.
Overview
LICART is a 10 cm x 14 cm topical system containing 1.3% diclofenac epolamine (182 mg per patch). The active ingredient is an NSAID presented as a topical adhesive system.
Uses
Indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
Dosage
The recommended dose is one patch applied once daily to the most painful area. Use the lowest effective dose for the shortest duration. Do not apply to damaged or non-intact skin. Avoid bathing or showering while wearing.
Side Effects
Most common reactions are localized application site pruritus and other skin reactions (irritation, erythema, rash, inflammation). Post-marketing reports include serious skin reactions: exfoliative dermatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis.
Interactions
Significant interactions include anticoagulants (increased bleeding risk), aspirin (GI toxicity risk), ACE inhibitors/ARBs (reduced efficacy, renal deterioration), diuretics, digoxin, lithium, methotrexate, cyclosporine, and pemetrexed.
Warnings
NSAIDs carry warnings regarding serious cardiovascular thrombotic events (myocardial infarction, stroke) that may be fatal, and serious gastrointestinal events (bleeding, ulceration, perforation). Contraindicated post-CABG surgery, with known hypersensitivity, or history of asthma/urticaria after aspirin or NSAIDs.
Pregnancy
Avoid use at approximately 30 weeks gestation and later due to fetal ductus arteriosus closure risk. Between 20-30 weeks, limit to lowest effective dose and shortest duration.
Storage
Store at 20-25 degrees C (68-77 degrees F). After opening the envelope, patches remain stable up to 6 months at room temperature.
Frequently Asked Questions
What is Diclofenac Epolamine used for?▼
Indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions.
What are the side effects of Diclofenac Epolamine?▼
Most common reactions are localized application site pruritus and other skin reactions (irritation, erythema, rash, inflammation). Post-marketing reports include serious skin reactions: exfoliative dermatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis.
Can I take Diclofenac Epolamine during pregnancy?▼
Avoid use at approximately 30 weeks gestation and later due to fetal ductus arteriosus closure risk. Between 20-30 weeks, limit to lowest effective dose and shortest duration.
What are the important warnings for Diclofenac Epolamine?▼
NSAIDs carry warnings regarding serious cardiovascular thrombotic events (myocardial infarction, stroke) that may be fatal, and serious gastrointestinal events (bleeding, ulceration, perforation). Contraindicated post-CABG surgery, with known hypersensitivity, or history of asthma/urticaria after aspirin or NSAIDs.
Related Medications
Acetaminophen, Diphenhydramine Hydrochloride, Zinc Acetate, Neomycin Sulfate, Polymyxin B Sulfate, And Pramoxine Hydrochloride
acetaminophen, diphenhydramine hydrochloride, zinc acetate, neomycin sulfate, polymyxin b sulfate, and pramoxine hydrochloride
Purpose Pain reliever/fever reducer
Voclosporin
voclosporin
Calcineurin Inhibitor Immunosuppressant [EPC]
11 DESCRIPTION LUPKYNIS (voclosporin) capsules, a calcineurin-inhibitor immunosuppressant, is available for administration as soft gelatin capsules containing 7.9 mg voclosporin per capsule. Inactive ingredients include alcohol, Vitamin E polyethylene glycol succinate (NF), polysorbate 40 (NF), medium-chain triglycerides (NF), gelatin, sorbitol, glycerin, iron oxide yellow, iron oxide red, titanium dioxide, and water. Voclosporin (90 to 95% trans -isomer) is the active ingredient in LUPKYNIS.
Guselkumab
guselkumab
Interleukin-23 Antagonist [EPC]
11 DESCRIPTION Guselkumab, an interleukin-23 antagonist, is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. Guselkumab is produced in a mammalian cell line using recombinant DNA technology and has an approximate molecular weight of approximately 147 kDa. TREMFYA ® (guselkumab) injection is a sterile, preservative free, clear, and colorless to light yellow solution.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.